This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
respiratory tract | 4477 |
acute respiratory | 3772 |
respiratory syncytial | 3404 |
syncytial virus | 3272 |
respiratory syndrome | 2761 |
respiratory viruses | 2624 |
lower respiratory | 1915 |
respiratory infections | 1642 |
severe acute | 1568 |
tract infections | 1341 |
viral infections | 1290 |
virus infection | 1220 |
human metapneumovirus | 1157 |
respiratory virus | 1073 |
syndrome coronavirus | 1031 |
upper respiratory | 1023 |
middle east | 972 |
influenza virus | 945 |
respiratory viral | 940 |
east respiratory | 932 |
tract infection | 882 |
respiratory distress | 879 |
intensive care | 862 |
respiratory disease | 846 |
respiratory infection | 840 |
respiratory illness | 834 |
respiratory failure | 792 |
rsv infection | 789 |
young children | 783 |
viral infection | 781 |
mechanical ventilation | 765 |
human bocavirus | 719 |
epithelial cells | 709 |
disease severity | 654 |
immune response | 648 |
distress syndrome | 643 |
respiratory pathogens | 632 |
virus infections | 618 |
viral respiratory | 613 |
risk factors | 595 |
respiratory symptoms | 594 |
parainfluenza virus | 533 |
transplant recipients | 519 |
acquired pneumonia | 517 |
viral load | 493 |
united states | 487 |
mg kg | 482 |
polymerase chain | 480 |
chain reaction | 476 |
porcine reproductive | 467 |
systematic review | 449 |
human coronavirus | 439 |
immune responses | 437 |
care unit | 432 |
doc id | 427 |
cord uid | 427 |
syndrome virus | 426 |
lung injury | 425 |
novel coronavirus | 425 |
influenza viruses | 423 |
health care | 401 |
infectious diseases | 389 |
human respiratory | 388 |
severe respiratory | 387 |
common cold | 381 |
pulmonary disease | 379 |
among children | 374 |
lung disease | 371 |
time pcr | 366 |
critically ill | 362 |
en el | 362 |
hospitalized children | 359 |
nucleic acid | 357 |
public health | 349 |
lung function | 349 |
sars coronavirus | 346 |
human rhinovirus | 344 |
saudi arabia | 338 |
severe disease | 334 |
tract disease | 330 |
may also | 330 |
immune system | 329 |
infection control | 320 |
hong kong | 315 |
chronic obstructive | 304 |
pacientes con | 301 |
asthma exacerbations | 299 |
coronavirus infection | 294 |
immunocompromised patients | 293 |
stem cell | 290 |
type i | 287 |
obstructive pulmonary | 285 |
respiratory diseases | 284 |
years old | 278 |
clinical characteristics | 270 |
multiplex pcr | 268 |
acute lower | 267 |
controlled trial | 266 |
cov infection | 265 |
prospective study | 264 |
acute lung | 262 |
streptococcus pneumoniae | 261 |
rhinovirus infection | 260 |
clinical features | 259 |
pediatric patients | 258 |
otitis media | 258 |
infected patients | 254 |
world health | 253 |
innate immune | 249 |
cohort study | 246 |
cell transplant | 244 |
children hospitalized | 244 |
increased risk | 243 |
clinical trials | 242 |
children aged | 242 |
viral replication | 241 |
influenza infection | 240 |
en pacientes | 238 |
hospitalized patients | 237 |
respiratory system | 236 |
health organization | 231 |
clinical signs | 230 |
least one | 229 |
reverse transcription | 227 |
control group | 227 |
viral etiology | 226 |
lung transplant | 226 |
clinical symptoms | 226 |
ill patients | 225 |
parainfluenza viruses | 225 |
viral rna | 225 |
virus detection | 224 |
statistically significant | 223 |
rsv infections | 222 |
se recomienda | 222 |
emergency department | 220 |
age groups | 219 |
present study | 218 |
dendritic cells | 218 |
sore throat | 216 |
human coronaviruses | 216 |
gene expression | 215 |
cystic fibrosis | 213 |
common respiratory | 213 |
bacterial infections | 212 |
coronavirus disease | 212 |
los pacientes | 212 |
age group | 209 |
septic shock | 205 |
neutralizing antibodies | 204 |
risk factor | 203 |
adult patients | 203 |
influenza vaccine | 201 |
high risk | 201 |
pcr assays | 199 |
intravenous drip | 199 |
rsv bronchiolitis | 199 |
respiratory illnesses | 198 |
respiratory rate | 196 |
viral pathogens | 196 |
mortality rate | 194 |
detection rate | 194 |
severe pneumonia | 190 |
bacterial pneumonia | 190 |
cell culture | 189 |
con covid | 188 |
pcr assay | 188 |
clinical trial | 187 |
bone marrow | 186 |
infections among | 185 |
bronchoalveolar lavage | 185 |
infl uenza | 184 |
sars patients | 183 |
like illness | 183 |
study period | 183 |
respiratory samples | 183 |
metapneumovirus infection | 177 |
secondary bacterial | 175 |
virus type | 175 |
infectious disease | 175 |
inflammatory response | 174 |
mycoplasma pneumoniae | 174 |
hematopoietic stem | 172 |
acute bronchiolitis | 171 |
older adults | 170 |
severe cases | 170 |
cell transplantation | 170 |
animal models | 170 |
two groups | 168 |
significantly higher | 168 |
clinical presentation | 166 |
rhinovirus infections | 165 |
significant differences | 165 |
pandemic influenza | 165 |
pulmonary function | 165 |
alveolar macrophages | 165 |
spike protein | 164 |
infected cells | 164 |
bacterial infection | 161 |
rna viruses | 161 |
viral pneumonia | 161 |
respiratory secretions | 161 |
significant difference | 160 |
first year | 159 |
nervous system | 159 |
patients admitted | 158 |
clinical manifestations | 158 |
nitric oxide | 157 |
severe bronchiolitis | 156 |
care workers | 155 |
airway epithelial | 153 |
tract illness | 153 |
pulmonary fibrosis | 153 |
heart disease | 152 |
frequently detected | 152 |
bacterial pathogens | 152 |
disease control | 152 |
staphylococcus aureus | 152 |
developing countries | 151 |
respiratory pathogen | 151 |
tidal volume | 151 |
clinical course | 150 |
lymph nodes | 149 |
healthcare workers | 149 |
mean age | 149 |
critical care | 149 |
oxygen saturation | 148 |
chronic lung | 146 |
severe rsv | 146 |
monoclonal antibody | 146 |
coronavirus infections | 145 |
clinical practice | 144 |
one study | 144 |
previous studies | 144 |
informed consent | 143 |
respiratory specimens | 142 |
virus bronchiolitis | 142 |
human parainfluenza | 142 |
important role | 141 |
hospital admission | 140 |
airway pressure | 140 |
en los | 140 |
performed using | 138 |
rsv disease | 138 |
lung tissue | 137 |
dromedary camels | 137 |
infection may | 137 |
central nervous | 136 |
median age | 136 |
mechanically ventilated | 136 |
interstitial pneumonia | 135 |
randomized controlled | 135 |
influenza vaccination | 134 |
viral detection | 134 |
clinical outcomes | 134 |
hematopoietic cell | 134 |
seasonal influenza | 134 |
acute viral | 133 |
gas exchange | 133 |
nasopharyngeal swabs | 133 |
heart failure | 133 |
viral loads | 133 |
case definition | 133 |
common cause | 133 |
airway obstruction | 132 |
children younger | 132 |
incubation period | 132 |
neutralizing antibody | 132 |
inflammatory cytokines | 131 |
viral shedding | 131 |
healthy children | 131 |
monoclonal antibodies | 130 |
avian influenza | 130 |
may occur | 129 |
causative agent | 129 |
host cell | 129 |
antimicrobial drugs | 128 |
patients infected | 128 |
recurrent wheezing | 127 |
pao fio | 127 |
type ii | 127 |
adaptive immune | 126 |
aged years | 126 |
nasopharyngeal aspirates | 126 |
virus disease | 125 |
pulmonary edema | 125 |
retrospective study | 125 |
bovine respiratory | 124 |
infection among | 124 |
within days | 124 |
may lead | 124 |
aspiration pneumonia | 124 |
among patients | 123 |
antibody response | 123 |
care units | 123 |
tested positive | 123 |
positive samples | 123 |
peripheral blood | 122 |
congenital heart | 122 |
lower airway | 122 |
pulmonary hypertension | 122 |
antibiotic therapy | 121 |
several studies | 121 |
el uso | 121 |
air pollution | 120 |
airway inflammation | 120 |
hajj pilgrims | 120 |
disease burden | 120 |
cell responses | 120 |
bronchiolitis obliterans | 120 |
associated pneumonia | 120 |
hospital stay | 120 |
organ failure | 119 |
respiratory support | 119 |
may cause | 118 |
diagnostic tests | 118 |
pregnant women | 117 |
chest wall | 117 |
recent study | 117 |
amino acid | 116 |
human adenovirus | 116 |
filmarray rp | 115 |
high prevalence | 115 |
human rhinoviruses | 115 |
may result | 115 |
rv infection | 115 |
cardiac output | 115 |
study group | 114 |
logistic regression | 114 |
nasal cavity | 114 |
multiplex real | 114 |
side effects | 114 |
electron microscopy | 114 |
acute otitis | 113 |
haemophilus influenzae | 113 |
lung cancer | 113 |
del paciente | 113 |
hbov infection | 112 |
infectious agents | 112 |
bocavirus infection | 112 |
structural proteins | 112 |
mortality rates | 111 |
respiratory panel | 111 |
upper airway | 111 |
antibiotic use | 111 |
control measures | 111 |
phylogenetic analysis | 111 |
recent studies | 111 |
blood pressure | 111 |
antiviral therapy | 110 |
south korea | 110 |
antibody responses | 110 |
virus replication | 109 |
blood flow | 109 |
leading cause | 108 |
innate immunity | 108 |
otherwise healthy | 108 |
viral bronchiolitis | 108 |
close contact | 107 |
cell lines | 107 |
alveolar damage | 107 |
renal failure | 106 |
tract samples | 106 |
associated coronavirus | 106 |
hmpv infection | 106 |
asthma exacerbation | 106 |
clinical impact | 105 |
clinical disease | 105 |
sample size | 105 |
viral culture | 105 |
pulmonary artery | 105 |
nucleic acids | 105 |
live attenuated | 105 |
among hospitalized | 104 |
adverse events | 104 |
severity score | 104 |
clinical samples | 104 |
viruses detected | 104 |
statistical analysis | 104 |
detection rates | 104 |
another study | 104 |
clinical specimens | 104 |
significantly lower | 104 |
viral co | 103 |
hospitalized infants | 103 |
epithelial cell | 102 |
marrow transplant | 102 |
immune cells | 101 |
nasopharyngeal swab | 101 |
severe lower | 101 |
newly discovered | 100 |
patients hospitalized | 100 |
diffuse alveolar | 100 |
para el | 100 |
healthy adults | 100 |
symptom onset | 100 |
previously healthy | 100 |
infections may | 99 |
early childhood | 99 |
pediatric intensive | 99 |
molecular epidemiology | 99 |
time rt | 98 |
wide range | 98 |
arterial blood | 98 |
per year | 98 |
adenovirus infection | 98 |
high levels | 97 |
mers coronavirus | 97 |
clinical diagnosis | 97 |
nucleocapsid protein | 97 |
hsct recipients | 97 |
preterm infants | 97 |
control study | 96 |
lung diseases | 96 |
combination therapy | 96 |
lower airways | 96 |
el paciente | 96 |
data suggest | 95 |
case report | 95 |
children admitted | 95 |
observational study | 95 |
adverse effects | 95 |
airway disease | 95 |
mouse model | 95 |
por covid | 94 |
aerosolized ribavirin | 94 |
coronavirus nl | 94 |
induced asthma | 94 |
early life | 94 |
acquired respiratory | 94 |
nasal swabs | 94 |
human beings | 94 |
adhesion molecule | 94 |
th responses | 94 |
heart rate | 94 |
chronic respiratory | 94 |
viral agents | 94 |
highly pathogenic | 93 |
hand hygiene | 93 |
coronavirus oc | 93 |
oxygen therapy | 93 |
acute asthma | 93 |
acid amplification | 93 |
coronavirus hku | 92 |
two patients | 92 |
blood samples | 92 |
con el | 92 |
endothelial cells | 92 |
year old | 92 |
clinical outcome | 92 |
clinical data | 92 |
even though | 92 |
adult respiratory | 92 |
requiring hospitalization | 92 |
ml kg | 92 |
host immune | 92 |
childhood asthma | 92 |
vaccine development | 91 |
chest radiograph | 91 |
inflammatory responses | 91 |
molecular methods | 91 |
severe illness | 91 |
older children | 91 |
antimicrobial drug | 91 |
direct contact | 91 |
infected children | 90 |
one patient | 90 |
blood gas | 90 |
essential oils | 90 |
nasal secretions | 90 |
children human | 89 |
may contribute | 89 |
bronchial epithelial | 89 |
nasopharyngeal aspirate | 89 |
higher risk | 89 |
converting enzyme | 88 |
high frequency | 88 |
icu admission | 88 |
acute wheezing | 88 |
infections caused | 87 |
chronic bronchitis | 87 |
among infants | 87 |
solid organ | 87 |
time polymerase | 87 |
bronchopulmonary dysplasia | 87 |
positive patients | 87 |
recent years | 87 |
antigen detection | 87 |
causative microorganisms | 86 |
may play | 86 |
icu patients | 86 |
authors declare | 86 |
primary infection | 86 |
samples collected | 86 |
like receptor | 86 |
five years | 86 |
protective equipment | 86 |
respiratory epithelium | 85 |
respiratory muscle | 85 |
antibiotic treatment | 85 |
study design | 85 |
ventilatory support | 85 |
age years | 85 |
human transmission | 84 |
nasal swab | 84 |
multiple organ | 84 |
pleural effusion | 84 |
closely related | 84 |
cell cultures | 84 |
fi rst | 84 |
within hours | 84 |
children years | 83 |
group i | 83 |
coronavirus associated | 83 |
host response | 83 |
natural killer | 83 |
acute phase | 83 |
respiratory drive | 83 |
necrosis factor | 83 |
rna polymerase | 82 |
ards patients | 82 |
underlying disease | 82 |
infl ammatory | 82 |
ventilated patients | 82 |
also found | 82 |
adenovirus type | 82 |
asthmatic children | 82 |
young adults | 82 |
airborne transmission | 82 |
high viral | 82 |
mononuclear cells | 81 |
clinical presentations | 81 |
respiratory epithelial | 81 |
hypertonic saline | 81 |
infections due | 81 |
time reverse | 81 |
controlled trials | 81 |
case series | 81 |
factors associated | 81 |
tract symptoms | 81 |
study population | 80 |
immunocompromised hosts | 80 |
patients may | 80 |
randomized clinical | 80 |
respiratory mechanics | 80 |
spinal cord | 80 |
clinical significance | 80 |
cotton rats | 80 |
clinical studies | 80 |
exact test | 80 |
global burden | 80 |
reactive protein | 79 |
supportive care | 79 |
supplemental oxygen | 79 |
important cause | 79 |
membrane oxygenation | 79 |
virus isolation | 79 |
rapid detection | 79 |
confidence interval | 79 |
apache ii | 79 |
experimental rhinovirus | 79 |
nasal congestion | 79 |
children less | 79 |
premature infants | 78 |
vivi disease | 78 |
hct recipients | 78 |
respiratory complications | 78 |
acute exacerbations | 78 |
general population | 78 |
resistant bacteria | 78 |
rsv vaccine | 78 |
copd patients | 78 |
novel human | 78 |
extracorporeal membrane | 77 |
hospital admissions | 77 |
university hospital | 77 |
ethics committee | 77 |
rapid diagnosis | 77 |
rna virus | 77 |
care facilities | 77 |
virus detected | 77 |
prrsv infection | 77 |
influenza vaccines | 77 |
identifi ed | 77 |
previously described | 76 |
acute infection | 76 |
complete genome | 76 |
antiviral agents | 76 |
simultaneous detection | 76 |
viral clearance | 76 |
rights reserved | 76 |
con sospecha | 76 |
commercially available | 76 |
stranded rna | 76 |
viral pathogen | 76 |
year period | 76 |
adenovirus infections | 76 |
major cause | 76 |
protective immunity | 75 |
birth cohort | 75 |
viral coinfection | 75 |
prospective cohort | 75 |
throat swabs | 75 |
fatal cases | 75 |
reverse transcriptase | 75 |
asymptomatic children | 75 |
without respiratory | 75 |
growth factor | 74 |
military recruits | 74 |
host cells | 74 |
nasal cannula | 74 |
patients without | 74 |
environmental factors | 74 |
new respiratory | 74 |
serum antibody | 74 |
airway hyperresponsiveness | 74 |
positive results | 73 |
influenza season | 73 |
lung transplantation | 73 |
community acquired | 73 |
confirmed cases | 73 |
transplant patients | 73 |
clinical severity | 73 |
proinflammatory cytokines | 73 |
inflammatory mediators | 73 |
cardiac surgery | 73 |
odds ratio | 73 |
case fatality | 73 |
personal protective | 73 |
nasal mucosa | 73 |
gold standard | 73 |
virus vaccine | 73 |
antiviral activity | 73 |
patient care | 73 |
children infected | 72 |
viral proteins | 72 |
paciente con | 72 |
nosocomial transmission | 72 |
mm hg | 72 |
young infants | 72 |
cytokine production | 72 |
significantly associated | 72 |
well tolerated | 72 |
large number | 72 |
smooth muscle | 72 |
randomised controlled | 72 |
previous reports | 71 |
nasal discharge | 71 |
relative humidity | 71 |
cause severe | 71 |
influenza pandemic | 71 |
respiratory protection | 71 |
respiratory droplets | 71 |
common viruses | 71 |
sin embargo | 71 |
respiratory infectious | 71 |
lung pathology | 71 |
ebola virus | 71 |
infect dis | 70 |
elderly patients | 70 |
widely used | 70 |
atypical pneumonia | 70 |
pneumonia requiring | 70 |
inflammatory cells | 70 |
commonly used | 70 |
influenza surveillance | 70 |
frequent detection | 70 |
genome sequence | 70 |
causative agents | 70 |
fusion protein | 70 |
better understanding | 70 |
organ transplant | 70 |
remains unclear | 69 |
north america | 69 |
white blood | 69 |
animal model | 69 |
patients treated | 69 |
infl ammation | 69 |
preventive measures | 69 |
tertiary care | 69 |
neuraminidase inhibitors | 69 |
previous study | 69 |
intercellular adhesion | 69 |
first years | 68 |
arterial pressure | 68 |
severe ards | 68 |
infants hospitalized | 68 |
multiplex rt | 68 |
body weight | 68 |
year study | 68 |
pseudomonas aeruginosa | 68 |
current study | 68 |
lung volume | 68 |
molecular diagnostics | 68 |
chest radiographs | 67 |
transport medium | 67 |
randomized trial | 67 |
high mortality | 67 |
disease progression | 67 |
one virus | 67 |
many cases | 67 |
face masks | 67 |
genetic diversity | 67 |
respiratory coronavirus | 66 |
physical examination | 66 |
nasopharyngeal secretions | 66 |
molecular techniques | 66 |
patients aged | 66 |
long term | 66 |
con un | 66 |
virus types | 66 |
fatality rate | 66 |
applied biosystems | 66 |
two cases | 66 |
herpes simplex | 66 |
patients undergoing | 66 |
relatively low | 66 |
cov infected | 65 |
multiple respiratory | 65 |
additional file | 65 |
tract specimens | 65 |
diagnostic testing | 65 |
lymphoid tissue | 65 |
hrv infection | 65 |
copies ml | 65 |
alveolar epithelial | 65 |
viral lower | 65 |
currently available | 65 |
nk cells | 65 |
computed tomography | 65 |
southern china | 65 |
studies suggest | 65 |
high rate | 65 |
term care | 65 |
situ hybridization | 64 |
months old | 64 |
acute rejection | 64 |
new human | 64 |
tissue culture | 64 |
determine whether | 64 |
host defense | 64 |
written informed | 64 |
pulmonary vascular | 64 |
healthy infants | 64 |
viral genome | 64 |
different respiratory | 63 |
ali ards | 63 |
patients receiving | 63 |
cell types | 63 |
pulmonary embolism | 63 |
newly identified | 63 |
flow nasal | 63 |
immune globulin | 63 |
convalescent plasma | 63 |
children respiratory | 63 |
studies using | 63 |
viral nucleic | 63 |
acute upper | 63 |
carbon dioxide | 63 |
lopinavir ritonavir | 63 |
differential diagnosis | 63 |
sars outbreak | 63 |
endotracheal intubation | 63 |
human airway | 63 |
sample collection | 62 |
copd exacerbations | 62 |
thoracic society | 62 |
expiratory flow | 62 |
en un | 62 |
mg twice | 62 |
multiplex reverse | 62 |
receptor binding | 62 |
giant cells | 62 |
human infection | 62 |
bacterial co | 62 |
rhinovirus colds | 62 |
statistical significance | 62 |
positive cases | 62 |
airway epithelium | 62 |
serum samples | 62 |
antibody titers | 62 |
real time | 62 |
may help | 61 |
winter months | 61 |
illness among | 61 |
sputum samples | 61 |
oral ribavirin | 61 |
less likely | 61 |
lung microbiome | 61 |
based study | 61 |
chlamydia pneumoniae | 61 |
multiple viruses | 61 |
human parvovirus | 61 |
may provide | 61 |
lavage fluid | 61 |
fl uid | 61 |
laboratory diagnosis | 61 |
acute exacerbation | 61 |
adaptive immunity | 60 |
healthy controls | 60 |
syncytial viruses | 60 |
signifi cant | 60 |
molecular assays | 60 |
respir viruses | 60 |
allergic rhinitis | 60 |
gastrointestinal tract | 60 |
three patients | 60 |
moraxella catarrhalis | 60 |
cell count | 60 |
arabian peninsula | 60 |
sialic acid | 60 |
cell surface | 60 |
commonly detected | 60 |
blood gases | 60 |
study conducted | 60 |
viral etiologies | 60 |
small number | 60 |
viral antigens | 60 |
antiviral drugs | 59 |
marrow transplantation | 59 |
increased susceptibility | 59 |
spontaneous breathing | 59 |
childhood pneumonia | 59 |
one case | 59 |
early diagnosis | 59 |
alveolar walls | 59 |
clinical management | 59 |
different viruses | 59 |
swab samples | 59 |
severe covid | 59 |
blood cell | 59 |
high incidence | 59 |
induced lung | 59 |
pressure support | 59 |
defense mechanisms | 59 |
total number | 59 |
test results | 59 |
patients presenting | 58 |
noninvasive ventilation | 58 |
patients died | 58 |
passive transfer | 58 |
endotracheal tube | 58 |
new york | 58 |
nursing home | 58 |
filmarray respiratory | 58 |
con una | 58 |
kg min | 58 |
el manejo | 58 |
antiviral treatment | 58 |
first days | 58 |
chest pain | 58 |
airway resistance | 58 |
infection induces | 57 |
diagnostic methods | 57 |
results suggest | 57 |
transcription polymerase | 57 |
severe asthma | 57 |
protective effect | 57 |
viruses may | 57 |
multicenter study | 57 |
diagnostic test | 57 |
primary care | 57 |
genetic variability | 57 |
lung inflammation | 57 |
tracheal intubation | 57 |
single infections | 57 |
south africa | 57 |
well known | 57 |
also observed | 57 |
one year | 57 |
inclusion criteria | 57 |
emerging respiratory | 57 |
infection rate | 57 |
viruses among | 57 |
virus vaccines | 57 |
metapneumovirus infections | 57 |
weight loss | 57 |
nasopharyngeal samples | 57 |
epidemiological studies | 57 |
disease caused | 57 |
hematologic malignancies | 57 |
severe clinical | 57 |
experimentally infected | 57 |
measles virus | 57 |
molecular diagnostic | 56 |
first hours | 56 |
runny nose | 56 |
prone positioning | 56 |
significantly different | 56 |
expiratory pressure | 56 |
regression analysis | 56 |
multivariate analysis | 56 |
respiratory function | 56 |
positive end | 56 |
different types | 56 |
cell death | 56 |
syndromic surveillance | 56 |
emergency room | 56 |
body temperature | 56 |
experimental infection | 56 |
predictive value | 56 |
detection methods | 56 |
data collection | 56 |
lung parenchyma | 56 |
many studies | 56 |
virus respiratory | 56 |
mers cov | 56 |
bacterial species | 56 |
phase ii | 55 |
cell line | 55 |
united kingdom | 55 |
bordetella pertussis | 55 |
institutional review | 55 |
vascular resistance | 55 |
three groups | 55 |
escherichia coli | 55 |
often associated | 55 |
laboratory tests | 55 |
common colds | 55 |
cytopathic effect | 54 |
risk infants | 54 |
atypical bacteria | 54 |
rapid antigen | 54 |
review board | 54 |
continuous variables | 54 |
severe influenza | 54 |
pulse oximetry | 54 |
hmpv infections | 54 |
cause respiratory | 54 |
febrile respiratory | 54 |
se debe | 54 |
myocardial infarction | 54 |
pulmonary infection | 54 |
surgical masks | 54 |
study showed | 54 |
kg times | 54 |
surgical mask | 54 |
dis doi | 54 |
idiopathic pulmonary | 54 |
patients received | 54 |
immune function | 54 |
tumor necrosis | 54 |
rna synthesis | 54 |
ml min | 53 |
new zealand | 53 |
mild upper | 53 |
two years | 53 |
i interferon | 53 |
uenza virus | 53 |
requiring mechanical | 53 |
dual infection | 53 |
tb patients | 53 |
por el | 53 |
forced expiratory | 53 |
por sars | 53 |
influenza infections | 53 |
common viral | 53 |
cough reflex | 53 |
elderly people | 53 |
study participants | 52 |
antimicrobial therapy | 52 |
se ha | 52 |
cytokine storm | 52 |
human influenza | 52 |
el riesgo | 52 |
mixed infections | 52 |
specific antibodies | 52 |
etiologic agent | 52 |
pg ml | 52 |
underlying conditions | 52 |
ct scan | 52 |
coronavirus spike | 52 |
early phase | 52 |
dry cough | 52 |
pacientes en | 52 |
severely ill | 52 |
open reading | 52 |
family members | 52 |
pilot study | 52 |
winter season | 51 |
seasonal distribution | 51 |
cell response | 51 |
lesser extent | 51 |
sequence analysis | 51 |
viral diagnosis | 51 |
two different | 51 |
infectious respiratory | 51 |
healthy individuals | 51 |
also known | 51 |
pasteurella multocida | 51 |
laboratory animals | 51 |
un estudio | 51 |
cigarette smoke | 51 |
acid extraction | 51 |
oxidative stress | 51 |
adenoviral infection | 51 |
immunocompromised children | 51 |
increased mortality | 51 |
negative results | 51 |
high fever | 51 |
virus pneumonia | 51 |
clinical relevance | 51 |
future studies | 51 |
lung ultrasound | 50 |
natural infection | 50 |
pathogen detection | 50 |
also cause | 50 |
care medicine | 50 |
birth weight | 50 |
cord blood | 50 |
human lung | 50 |
infection prevention | 50 |
medical center | 50 |
rhodococcus equi | 50 |
laboratory testing | 50 |
sars cov | 50 |
positive airway | 50 |
less frequently | 50 |
pneumonia caused | 50 |
community respiratory | 50 |
bacterial respiratory | 50 |
human disease | 50 |
studies conducted | 50 |
klebsiella pneumoniae | 50 |
viral disease | 50 |
central venous | 50 |
mg dl | 50 |
study found | 50 |
study protocol | 50 |
case definitions | 50 |
discovered human | 50 |
high morbidity | 50 |
tube assay | 50 |
using multiplex | 50 |
molecular detection | 50 |
associated hospitalizations | 50 |
prolonged shedding | 50 |
preschool children | 49 |
infection respiratory | 49 |
medical records | 49 |
expiratory wheezing | 49 |
competing interests | 49 |
twice daily | 49 |
maternal antibodies | 49 |
cellular immune | 49 |
drug therapy | 49 |
strongly associated | 49 |
interstitial lung | 49 |
inhaled nitric | 49 |
taken together | 49 |
laboratory findings | 49 |
host factors | 49 |
risk patients | 49 |
overall mortality | 49 |
medical conditions | 49 |
inflammatory process | 49 |
face mask | 49 |
confirmed influenza | 49 |
retrospective analysis | 49 |
one respiratory | 49 |
small airways | 49 |
hrv infections | 48 |
infected individuals | 48 |
like protease | 48 |
pneumococcal pneumonia | 48 |
also associated | 48 |
kg day | 48 |
mycobacterium tuberculosis | 48 |
acute samples | 48 |
severe infections | 48 |
medical care | 48 |
negative pressure | 48 |
human adenoviruses | 48 |
specimen collection | 48 |
among young | 48 |
acute gastroenteritis | 48 |
lung biopsy | 48 |
viral panel | 48 |
group ii | 48 |
common symptoms | 48 |
xtag rvp | 48 |
fi brosis | 48 |
diseases society | 48 |
early stages | 48 |
evidence suggests | 48 |
tobacco smoke | 48 |
parainfl uenza | 48 |
multiple viral | 48 |
i ifn | 48 |
elderly adults | 48 |
cardiac arrest | 48 |
human immunodeficiency | 48 |
infectious virus | 48 |
virus culture | 48 |
infection human | 48 |
immunodeficiency virus | 48 |
healthy subjects | 47 |
ng ml | 47 |
blood cells | 47 |
viral agent | 47 |
symptomatic patients | 47 |
without symptoms | 47 |
data analysis | 47 |
severe infection | 47 |
critical illness | 47 |
common causes | 47 |
intravenous immunoglobulin | 47 |
throat swab | 47 |
virus transmission | 47 |
airflow obstruction | 47 |
viruses using | 47 |
using pcr | 47 |
allergic inflammation | 47 |
five patients | 47 |
single infection | 47 |
per day | 47 |
molecular biology | 47 |
clinically relevant | 47 |
asymptomatic infection | 47 |
previously reported | 47 |
using real | 47 |
cuidados intensivos | 47 |
communityacquired pneumonia | 47 |
old children | 47 |
high rates | 47 |
th cytokine | 47 |
less common | 47 |
transplant recipient | 47 |
three different | 47 |
dipeptidyl peptidase | 47 |
supplementary material | 47 |
care settings | 47 |
infected mice | 47 |
stool samples | 47 |
infection occurs | 47 |
interstitial fibrosis | 47 |
plasma cells | 46 |
based studies | 46 |
square test | 46 |
en las | 46 |
th cells | 46 |
many patients | 46 |
viruses associated | 46 |
like strains | 46 |
acute bronchitis | 46 |
measured using | 46 |
like receptors | 46 |
findings suggest | 46 |
sputum production | 46 |
pcr test | 46 |
may reduce | 46 |
amino acids | 46 |
broad spectrum | 46 |
poorly understood | 46 |
tract viral | 46 |
middle ear | 46 |
hospital mortality | 46 |
described previously | 46 |
also detected | 46 |
simplex virus | 46 |
se puede | 46 |
chest radiography | 46 |
diagnostic tools | 46 |
asthmatic patients | 46 |
acute illness | 46 |
prospective studies | 46 |
day care | 46 |
children without | 46 |
molecular screening | 46 |
whole blood | 46 |
swab specimens | 46 |
new virus | 46 |
results showed | 45 |
structural protein | 45 |
lactate dehydrogenase | 45 |
blood cultures | 45 |
early detection | 45 |
may explain | 45 |
connective tissue | 45 |
clinical picture | 45 |
may develop | 45 |
health authorities | 45 |
several days | 45 |
positive pressure | 45 |
viral particles | 45 |
lung infection | 45 |
least two | 45 |
th response | 45 |
rsv load | 45 |
patient population | 45 |
vp vp | 45 |
tissue damage | 45 |
categorical variables | 45 |
hospitalizations among | 45 |
less severe | 45 |
analysis showed | 45 |
drug administration | 45 |
prone position | 45 |
see table | 45 |
mucus production | 45 |
human pneumovirus | 45 |
blood mononuclear | 45 |
pcr testing | 45 |
respiratory health | 45 |
oral administration | 45 |
immunocompromised adults | 44 |
th th | 44 |
based surveillance | 44 |
pcr system | 44 |
wide variety | 44 |
national institute | 44 |
phase iii | 44 |
corona virus | 44 |
bronchitis virus | 44 |
dependent rna | 44 |
invasive ventilation | 44 |
viral transport | 44 |
congestive heart | 44 |
severe sepsis | 44 |
rainy season | 44 |
increased levels | 44 |
also contribute | 44 |
predictive factors | 44 |
mice infected | 44 |
secondary infections | 44 |
rhesus macaques | 44 |
mast cells | 44 |
recurrent respiratory | 44 |
reverse genetics | 44 |
ii pneumonocytes | 44 |
first months | 44 |
turnaround time | 44 |
rsv replication | 43 |
table ii | 43 |
pneumoniae infection | 43 |
hospitalization among | 43 |
lactate levels | 43 |
positive cells | 43 |
two viruses | 43 |
ii score | 43 |
pneumonia among | 43 |
spike glycoprotein | 43 |
productive cough | 43 |
respiratory tracts | 43 |
cell membrane | 43 |
hemorrhagic fever | 43 |
el tratamiento | 43 |
pulmonary oedema | 43 |
acute renal | 43 |
pneumovirus isolated | 43 |
exclusion criteria | 43 |
high sensitivity | 43 |
transmission dynamics | 43 |
mild respiratory | 43 |
emergency departments | 43 |
mg day | 43 |
respiratory depression | 43 |
children attending | 43 |
gastrointestinal symptoms | 43 |
underlying diseases | 43 |
specific viral | 43 |
low levels | 43 |
first week | 43 |
single virus | 43 |
severe viral | 43 |
induced pulmonary | 43 |
allogeneic hematopoietic | 43 |
nonstructural protein | 43 |
less frequent | 43 |
hadv infection | 43 |
flow rate | 43 |
sars virus | 43 |
disease associated | 43 |
swine influenza | 43 |
inflammatory cytokine | 43 |
allergic sensitization | 43 |
organ dysfunction | 43 |
nipah virus | 43 |
rvp fast | 43 |
el grupo | 43 |
care facility | 42 |
binding domain | 42 |
hiv infection | 42 |
aerosol transmission | 42 |
specific cd | 42 |
vaccine effectiveness | 42 |
pulmonary lesions | 42 |
multiple sclerosis | 42 |
additional information | 42 |
higher mortality | 42 |
pediatric population | 42 |
bal fluid | 42 |
droplet nuclei | 42 |
viral entry | 42 |
human enterovirus | 42 |
cov infections | 42 |
adults hospitalized | 42 |
viral dna | 42 |
breathing pattern | 42 |
including influenza | 42 |
pressure ventilation | 42 |
infectious bronchitis | 42 |
rapid diagnostic | 42 |
surveillance system | 42 |
infection due | 42 |
commonly associated | 42 |
children presenting | 42 |
orally administered | 42 |
symptoms may | 42 |
pcr products | 42 |
aged less | 42 |
korean children | 42 |
ill children | 42 |
arterial oxygen | 42 |
may become | 42 |
respiratory effort | 42 |
identifi cation | 42 |
mini kit | 42 |
hcov infections | 42 |
viral titers | 42 |
animal studies | 42 |
elderly persons | 42 |
diagnostic techniques | 42 |
clinical findings | 42 |
en una | 41 |
vitro studies | 41 |
sari cases | 41 |
antigen tests | 41 |
literature review | 41 |
potential role | 41 |
functional receptor | 41 |
high concentrations | 41 |
may require | 41 |
expression levels | 41 |
study using | 41 |
asymptomatic infections | 41 |
multiple infections | 41 |
virus lower | 41 |
like illnesses | 41 |
transcriptase polymerase | 41 |
lung damage | 41 |
healthy young | 41 |
healthcare settings | 41 |
significantly reduced | 41 |
blood vessels | 41 |
bacterial colonization | 41 |
frequently associated | 41 |
antiviral response | 41 |
remains unknown | 41 |
chlamydophila pneumoniae | 41 |
respiratory muscles | 41 |
higher levels | 41 |
year prospective | 41 |
bacterial coinfection | 41 |
pneumococcal disease | 41 |
significant increase | 41 |
mucociliary clearance | 41 |
cd cells | 41 |
asymptomatic patients | 40 |
developed countries | 40 |
free days | 40 |
rna genome | 40 |
longitudinal study | 40 |
intravenous injection | 40 |
asthma symptoms | 40 |
coronavirus replication | 40 |
hypoxemic respiratory | 40 |
mean duration | 40 |
plasmacytoid dendritic | 40 |
respiratory society | 40 |
higher incidence | 40 |
fio ratio | 40 |
th cytokines | 40 |
four patients | 40 |
mg ml | 40 |
fluorescent antibody | 40 |
viral antigen | 40 |
cell entry | 40 |
significantly increased | 40 |
febrile illness | 40 |
replacement therapy | 40 |
will help | 40 |
severe symptoms | 40 |
internal control | 40 |
mortality associated | 40 |
seasonal pattern | 40 |
relative risk | 40 |
lymphocyte count | 40 |
epidemiologic studies | 40 |
reduced lung | 40 |
general practice | 40 |
mean arterial | 40 |
also reported | 39 |
last years | 39 |
plasma convaleciente | 39 |
economic burden | 39 |
unclear whether | 39 |
survival rate | 39 |
renal function | 39 |
inspiratory effort | 39 |
hospital discharge | 39 |
identified respiratory | 39 |
diagnostic assays | 39 |
causing respiratory | 39 |
drug susceptibility | 39 |
pediatric respiratory | 39 |
continuous positive | 39 |
severe community | 39 |
controlled study | 39 |
gestational age | 39 |
por lo | 39 |
sbt abpc | 39 |
tidal volumes | 39 |
standard deviation | 39 |
nosocomial infections | 39 |
bacterial superinfection | 39 |
mouse models | 39 |
highly sensitive | 39 |
infected animals | 39 |
inactivated influenza | 39 |
risk children | 39 |
corticosteroid therapy | 39 |
defi ned | 39 |
lymphoid tissues | 39 |
sense rna | 39 |
illness severity | 39 |
neonatal intensive | 39 |
infection using | 39 |
brain injury | 39 |
positive specimens | 39 |
sars cases | 39 |
per minute | 39 |
three times | 39 |
well established | 39 |
may include | 39 |
time course | 39 |
infections human | 39 |
global health | 39 |
therapeutic strategies | 39 |
healthy volunteers | 38 |
trauma patients | 38 |
tract illnesses | 38 |
many years | 38 |
significant correlation | 38 |
infection rates | 38 |
american thoracic | 38 |
pleural effusions | 38 |
first time | 38 |
en cuenta | 38 |
infi ltrates | 38 |
monkey kidney | 38 |
vaccine candidate | 38 |
respiratory syndromes | 38 |
room air | 38 |
two main | 38 |
month period | 38 |
invasive mechanical | 38 |
viruses causing | 38 |
nasal wash | 38 |
sectional study | 38 |
asthma development | 38 |
chronic diseases | 38 |
potential pathogens | 38 |
demographic characteristics | 38 |
ifv infection | 38 |
pulmonary tuberculosis | 38 |
rsv season | 38 |
common virus | 38 |
virus load | 38 |
molecular characterization | 38 |
pulmonary infections | 38 |
military personnel | 38 |
hand washing | 38 |
new viruses | 38 |
retrospective cohort | 38 |
study reported | 38 |
membrane fusion | 38 |
mortality among | 38 |
specimens collected | 38 |
allergic asthma | 38 |
clinical utility | 38 |
table i | 38 |
large numbers | 38 |
inactivated vaccine | 38 |
emerging infectious | 38 |
family history | 38 |
among adults | 38 |
specific treatment | 38 |
children may | 38 |
nonstructural proteins | 38 |
cold symptoms | 38 |
induced sputum | 38 |
infants born | 38 |
icu stay | 38 |
hexon gene | 37 |
routine use | 37 |
viruses including | 37 |
obstructive lung | 37 |
positive rate | 37 |
diabetes mellitus | 37 |
regression model | 37 |
antiviral immunity | 37 |
analyzed using | 37 |
inhaled corticosteroids | 37 |
clinical evidence | 37 |
human cases | 37 |
increased severity | 37 |
included patients | 37 |
mannheimia haemolytica | 37 |
vaccine candidates | 37 |
samples obtained | 37 |
cell type | 37 |
molecular epidemiological | 37 |
poor prognosis | 37 |
generating procedures | 37 |
laboratory data | 37 |
also showed | 37 |
early stage | 37 |
atypical bacterial | 37 |
may increase | 37 |
hospitalization rates | 37 |
pcr tests | 37 |
like particles | 37 |
foreign body | 37 |
vast majority | 37 |
induced acute | 37 |
among us | 37 |
rsv lower | 37 |
post infection | 37 |
wheezing episodes | 37 |
signifi cantly | 37 |
acute febrile | 37 |
quality control | 37 |
infections occur | 37 |
airway hyperreactivity | 37 |
higher rates | 37 |
nuclear factor | 37 |
medical history | 37 |
oxygen delivery | 37 |
clinical evaluation | 37 |
class i | 37 |
assisted ventilation | 37 |
virus isolated | 37 |
paediatric intensive | 36 |
acute expiratory | 36 |
virus shedding | 36 |
nested pcr | 36 |
right ventricular | 36 |
expiratory volume | 36 |
picu admission | 36 |
gas analysis | 36 |
small sample | 36 |
significant morbidity | 36 |
domestic animals | 36 |
temperate climates | 36 |
respiratory bacteria | 36 |
tract viruses | 36 |
detected viruses | 36 |
cell activation | 36 |
molecular tests | 36 |
pathogens detected | 36 |
asthma control | 36 |
induced wheezing | 36 |
gut microbiome | 36 |
common clinical | 36 |
surveillance study | 36 |
hbov positive | 36 |
hospital setting | 36 |
human monoclonal | 36 |
subsequent development | 36 |
detected virus | 36 |
cardiac index | 36 |
porcine respiratory | 36 |
six patients | 36 |
will also | 36 |
increased respiratory | 36 |
cytokine responses | 36 |
inspiratory pressure | 36 |
immunosuppressed patients | 36 |
experimental studies | 36 |
dual infections | 36 |
upper airways | 36 |
broad range | 36 |
mycoplasma hyopneumoniae | 36 |
disease transmission | 36 |
pathological changes | 36 |
atopic dermatitis | 36 |
associated lymphoid | 36 |
better understand | 36 |
porcine circovirus | 35 |
canine respiratory | 35 |
infection caused | 35 |
cell receptor | 35 |
plasminogen activator | 35 |
nosocomial infection | 35 |
african green | 35 |
control subjects | 35 |
nursing homes | 35 |
cov rna | 35 |
head injury | 35 |
require hospitalization | 35 |
highly contagious | 35 |
patients requiring | 35 |
also seen | 35 |
plasma levels | 35 |
detect respiratory | 35 |
highly conserved | 35 |
pulmonary alveolar | 35 |
isolator piglets | 35 |
two consecutive | 35 |
antimicrobial activity | 35 |
indigenous infants | 35 |
lymph node | 35 |
high doses | 35 |
nasal microbiota | 35 |
invasive pneumococcal | 35 |
cytokines chemokines | 35 |
compared using | 35 |
meteorological parameters | 35 |
observational studies | 35 |
possible cause | 35 |
reported cases | 35 |
nasopharyngeal specimens | 35 |
functional residual | 35 |
common among | 35 |
adult population | 35 |
nasal washes | 35 |
attenuated influenza | 35 |
specific antibody | 35 |
oxygen consumption | 35 |
patients required | 35 |
dendritic cell | 35 |
median duration | 35 |
chronic disease | 35 |
diffi cult | 35 |
single dose | 35 |
cells may | 35 |
linear regression | 35 |
illness associated | 35 |
epidemiological data | 35 |
van den | 35 |
nucleotide sequences | 35 |
protease inhibitors | 35 |
residual capacity | 35 |
controlled clinical | 35 |
body mass | 35 |
like symptoms | 34 |
affected foals | 34 |
nk cell | 34 |
hospitalized adults | 34 |
will need | 34 |
respiratory signs | 34 |
organ cultures | 34 |
one must | 34 |
disease due | 34 |
oxygen requirement | 34 |
practice guidelines | 34 |
novel viruses | 34 |
hyaline membrane | 34 |
natural history | 34 |
risk groups | 34 |
humoral immunity | 34 |
dna viruses | 34 |
clinical syndromes | 34 |
generation sequencing | 34 |
united arab | 34 |
diagnostic accuracy | 34 |
million deaths | 34 |
hepatitis virus | 34 |
high dose | 34 |
treatment options | 34 |
neuraminidase inhibitor | 34 |
viral illness | 34 |
respiratory problems | 34 |
systematic analysis | 34 |
key role | 34 |
clinical illness | 34 |
patient management | 34 |
airway function | 34 |
statistical analyses | 34 |
virus panel | 34 |
ciliated cells | 34 |
previously published | 34 |
coronavirus pneumonia | 34 |
close contacts | 34 |
severity scores | 34 |
mean temperature | 34 |
systemic symptoms | 34 |
immunofluorescence assay | 34 |
arab emirates | 34 |
immunocompromised persons | 34 |
oxygen supplementation | 34 |
postoperative period | 34 |
infants younger | 34 |
human bocaviruses | 34 |
serum antibodies | 34 |
clinical decision | 34 |
demographic data | 34 |
studies showed | 34 |
allergen exposure | 34 |
cellular immunity | 34 |
household members | 34 |
patients showed | 34 |
cerebrospinal fluid | 34 |
etiologic agents | 34 |
seasonal variation | 34 |
paramyxoviridae family | 33 |
obliterans syndrome | 33 |
independent risk | 33 |
xtag respiratory | 33 |
viral coinfections | 33 |
adenoviral infections | 33 |
blood culture | 33 |
microbial load | 33 |
least days | 33 |
aged children | 33 |
international committee | 33 |
liver disease | 33 |
todos los | 33 |
influenza respiratory | 33 |
among hajj | 33 |
bovine viral | 33 |
recurrent wheeze | 33 |
three years | 33 |
associated respiratory | 33 |
clinical spectrum | 33 |
additional studies | 33 |
virus challenge | 33 |
con los | 33 |
viral causes | 33 |
chronic cough | 33 |
chronic asthma | 33 |
cell activity | 33 |
nasal passages | 33 |
age range | 33 |
disease human | 33 |
included studies | 33 |
significant changes | 33 |
multiplex assays | 33 |
killer cells | 33 |
term infants | 33 |
protective ventilation | 33 |
interstitial pneumonitis | 33 |
interquartile range | 33 |
asthmatic subjects | 33 |
infectious agent | 33 |
muscle weakness | 33 |
secondary infection | 33 |
antimicrobial agents | 33 |
years ago | 33 |
important risk | 33 |
contact tracing | 33 |
virus may | 33 |
fi ndings | 33 |
droplet transmission | 33 |
prospective multicenter | 33 |
immune systems | 33 |
enhanced disease | 33 |
study respiratory | 33 |
different age | 33 |
legionella pneumophila | 33 |
among pilgrims | 33 |
exogenous surfactant | 33 |
well described | 33 |
hematologic malignancy | 33 |
short term | 33 |
pneumococcal vaccine | 33 |
sars infection | 33 |
virus immune | 33 |
higher viral | 33 |
bronchial asthma | 33 |
much less | 33 |
treatment group | 33 |
descriptive study | 33 |
among different | 33 |
acid sequence | 33 |
sendai virus | 33 |
alveolar epithelium | 33 |
etiological agent | 33 |
severe pulmonary | 33 |
also shown | 33 |
new insights | 33 |
confidence intervals | 33 |
persistent infection | 33 |
fatty acids | 33 |
novel influenza | 32 |
blood count | 32 |
disseminated intravascular | 32 |
first study | 32 |
high level | 32 |
relative abundance | 32 |
clinical research | 32 |
hyaline membranes | 32 |
amplification tests | 32 |
induced airway | 32 |
primer sets | 32 |
income countries | 32 |
infect humans | 32 |
viral diarrhea | 32 |
respiratory status | 32 |
disease onset | 32 |
transmission routes | 32 |
pulmonary inflammation | 32 |
cardiogenic shock | 32 |
virus strains | 32 |
humoral immune | 32 |
mild disease | 32 |
working group | 32 |
two major | 32 |
rv infections | 32 |
mucous membranes | 32 |
target cells | 32 |
airway responsiveness | 32 |
pulmonary interstitial | 32 |
febrile neutropenia | 32 |
venous blood | 32 |
linked immunosorbent | 32 |
virus among | 32 |
pneumonia etiology | 32 |
guangdong province | 32 |
every year | 32 |
squamous metaplasia | 32 |
lung mechanics | 32 |
diagnostic procedures | 32 |
days later | 32 |
one third | 32 |
seasonal patterns | 32 |
conducted using | 32 |
positivity rate | 32 |
adhesion molecules | 32 |
paediatric patients | 32 |
high proportion | 32 |
confi rmed | 32 |
viral testing | 32 |
study also | 32 |
symptomatic children | 32 |
household contacts | 32 |
pattern recognition | 32 |
increased disease | 32 |
coding region | 32 |
mouse hepatitis | 31 |
health problem | 31 |
cov spike | 31 |
nutritional status | 31 |
adenoid tissue | 31 |
year follow | 31 |
nebulized hypertonic | 31 |
naturally occurring | 31 |
bronchiolitis severity | 31 |
among health | 31 |
ace receptor | 31 |
prolonged viral | 31 |
takes place | 31 |
pulmonary infiltrates | 31 |
mers cases | 31 |
mucosal immune | 31 |
mediated immunity | 31 |
en su | 31 |
clinical respiratory | 31 |
ex vivo | 31 |
agarose gel | 31 |
first step | 31 |
study included | 31 |
infection causes | 31 |
pneumonic mannheimiosis | 31 |
clinical settings | 31 |
significant decrease | 31 |
may persist | 31 |
advisory committee | 31 |
respiratory agents | 31 |
diseases among | 31 |
viral aetiology | 31 |
pneumonia cases | 31 |
family paramyxoviridae | 31 |
age distribution | 31 |
neuromuscular blockade | 31 |
reading frames | 31 |
younger children | 31 |
pulmonary diseases | 31 |
severe complications | 31 |
neutrophil extracellular | 31 |
immunocompromised individuals | 31 |
staff members | 31 |
first described | 31 |
case reports | 31 |
probably due | 31 |
chronic pulmonary | 31 |
cytokine response | 31 |
multiorgan failure | 31 |
available data | 31 |
economic impact | 31 |
cov replication | 31 |
allergic airway | 31 |
data indicate | 31 |
adults respiratory | 31 |
surfactant therapy | 31 |
beneficial effects | 31 |
critical role | 31 |
increased expression | 31 |
lung compliance | 31 |
patient groups | 31 |
control groups | 31 |
cohort studies | 31 |
national health | 31 |
much lower | 31 |
elevated levels | 31 |
adult lung | 31 |
frequently isolated | 31 |
french pilgrims | 31 |
medically attended | 31 |
illness caused | 31 |
one may | 31 |
virus associated | 31 |
stranded dna | 31 |
important respiratory | 31 |
enrolled patients | 31 |
disease may | 31 |
epidemiological characteristics | 31 |
serious bacterial | 31 |
membrane protein | 31 |
coronavirus rna | 31 |
current status | 31 |
practice guideline | 31 |
electron microscopic | 30 |
negative bacteria | 30 |
clinical use | 30 |
piv infections | 30 |
human subjects | 30 |
become available | 30 |
infection symptoms | 30 |
acute onset | 30 |
lung lesions | 30 |
may vary | 30 |
ribavirin therapy | 30 |
clinical criteria | 30 |
antibody titer | 30 |
induced respiratory | 30 |
host range | 30 |
indigenous peoples | 30 |
time period | 30 |
antiviral immune | 30 |
australian children | 30 |
significant association | 30 |
cell proliferation | 30 |
young age | 30 |
fecal samples | 30 |
immunosorbent assay | 30 |
cause disease | 30 |
endoplasmic reticulum | 30 |
tropical countries | 30 |
dna vaccines | 30 |
viruses cause | 30 |
se han | 30 |
clinical microbiology | 30 |
viruses identified | 30 |
nosocomial respiratory | 30 |
specific respiratory | 30 |
may present | 30 |
requiring intensive | 30 |
patients developed | 30 |
attack rate | 30 |
spectrum antiviral | 30 |
rsv illness | 30 |
early spring | 30 |
higher rate | 30 |
respiratory symptom | 30 |
urinary tract | 30 |
leading causes | 30 |
widespread use | 30 |
necrotizing enterocolitis | 30 |
severe combined | 30 |
studies reported | 30 |
transmission within | 30 |
function tests | 30 |
cell counts | 30 |
inflammatory markers | 30 |
infections occurred | 30 |
molecular evolution | 30 |
intravascular coagulation | 30 |
relatively high | 30 |
shell vial | 30 |
canine infectious | 30 |
en uci | 30 |
parainfluenza type | 30 |
life support | 30 |
frequent cause | 30 |
might also | 30 |
particle size | 30 |
effective vaccine | 30 |
swabs collected | 30 |
th day | 30 |
healthcare professionals | 30 |
neonatal isoerythrolysis | 30 |
may represent | 30 |
nasal obstruction | 30 |
hospital length | 30 |
normal range | 30 |
per se | 30 |
clinical effects | 30 |
days post | 30 |
surveillance data | 30 |
control practices | 30 |
effi cacy | 30 |
several weeks | 29 |
average age | 29 |
many viruses | 29 |
human rsv | 29 |
develop severe | 29 |
nosocomial pneumonia | 29 |
diarrhea virus | 29 |
samples using | 29 |
data available | 29 |
similar results | 29 |
virus rna | 29 |
tract involvement | 29 |
cystic fi | 29 |
cold virus | 29 |
lung volumes | 29 |
southern hemisphere | 29 |
different viral | 29 |
antibiotic resistance | 29 |
los estudios | 29 |
three cases | 29 |
surface glycoproteins | 29 |
severely affected | 29 |
cells infected | 29 |
alveolar macrophage | 29 |
among others | 29 |
virus strain | 29 |
molecular testing | 29 |
viral envelope | 29 |
first identified | 29 |
frequently reported | 29 |
bronchiolar epithelium | 29 |
considered statistically | 29 |
cardiovascular disease | 29 |
recognition receptors | 29 |
cardiac disease | 29 |
specific antiviral | 29 |
quantitative pcr | 29 |
much higher | 29 |
odds ratios | 29 |
successful treatment | 29 |
sars epidemic | 29 |
pcr method | 29 |
creative commons | 29 |
gene sequences | 29 |
rescue therapy | 29 |
pcr amplification | 29 |
children clinical | 29 |
community cohort | 29 |
will provide | 29 |
oscillatory ventilation | 29 |
physical activity | 29 |
jugular bulb | 29 |
signaling pathways | 29 |
normal subjects | 29 |
patients included | 29 |
probable sars | 29 |
summer months | 29 |
molecular mechanisms | 29 |
fold increase | 29 |
consecutive years | 29 |
transforming growth | 29 |
factors may | 29 |
sickle cell | 29 |
enzootic pneumonia | 29 |
viral cultures | 29 |
underlying medical | 29 |
north american | 29 |
rsv detection | 29 |
viral diseases | 29 |
combined immunodeficiency | 29 |
also may | 29 |
major role | 29 |
recipients respiratory | 29 |
major respiratory | 29 |
su uso | 29 |
cancer patients | 29 |
related pneumonia | 29 |
positive result | 29 |
multiplex polymerase | 29 |
med doi | 29 |
transcription factor | 29 |
van der | 29 |
regulatory factor | 29 |
plos one | 29 |
luminex xtag | 29 |
early treatment | 29 |
pulmonary syndrome | 29 |
two weeks | 29 |
neurological diseases | 29 |
i ifns | 29 |
nasal aspirates | 29 |
nitrogen dioxide | 29 |
may affect | 29 |
southeast asia | 29 |
fatal outcome | 29 |
molecular diagnosis | 29 |
tumour necrosis | 29 |
red blood | 29 |
table shows | 29 |
envelope protein | 29 |
may improve | 29 |
children older | 29 |
main cause | 29 |
bovine coronavirus | 29 |
epidemiological study | 29 |
negative group | 28 |
positive control | 28 |
pneumonia associated | 28 |
tracheal aspirates | 28 |
pathogenic bacteria | 28 |
etiologic role | 28 |
seven patients | 28 |
vp gene | 28 |
neonatal respiratory | 28 |
therapeutic interventions | 28 |
older age | 28 |
highest risk | 28 |
positive predictive | 28 |
frequency oscillatory | 28 |
como el | 28 |
commonly found | 28 |
clinical manifestation | 28 |
cov outbreak | 28 |
fisher exact | 28 |
cause pneumonia | 28 |
clinical efficacy | 28 |
ii rv | 28 |
virus particles | 28 |
deficient mice | 28 |
time points | 28 |
hbov infections | 28 |
short period | 28 |
surface area | 28 |
pneumococcal vaccination | 28 |
presenting cells | 28 |
nasal spray | 28 |
virol doi | 28 |
genome sequences | 28 |
abdominal pain | 28 |
although rsv | 28 |
metabolic acidosis | 28 |
symptom scores | 28 |
influenza cases | 28 |
nasal epithelial | 28 |
bordetella bronchiseptica | 28 |
per week | 28 |
limited number | 28 |
surgical patients | 28 |
respiratory disorders | 28 |
con sdra | 28 |
es un | 28 |
respiratory sample | 28 |
den hoogen | 28 |
methods used | 28 |
initial treatment | 28 |
particulate matter | 28 |
sensitive molecular | 28 |
among military | 28 |
one hour | 28 |
older persons | 28 |
children using | 28 |
us military | 28 |
nasal epithelium | 28 |
influenza pneumonia | 28 |
relatively small | 28 |
arabia middle | 28 |
function testing | 28 |
every day | 28 |
enzyme immunoassay | 28 |
high degree | 28 |
also important | 28 |
contact precautions | 28 |
phase i | 28 |
ct findings | 28 |
independently associated | 28 |
heart surgery | 28 |
induced bronchiolitis | 28 |
may induce | 28 |
limited data | 28 |
executive summary | 28 |
required mechanical | 28 |
debe ser | 28 |
tested negative | 28 |
empiric therapy | 28 |
asymptomatic controls | 28 |
newly described | 28 |
negative patients | 28 |
rsv cases | 28 |
respiratory morbidity | 28 |
low risk | 28 |
transplantation recipients | 28 |
infected epithelial | 28 |
low viral | 28 |
clinically significant | 28 |
detecting respiratory | 28 |
antigen presentation | 28 |
last decade | 28 |
virus circulation | 28 |
community study | 28 |
treatment strategies | 28 |
increased airway | 28 |
study demonstrated | 28 |
left ventricular | 28 |
syncytial viral | 28 |
tissue samples | 28 |
children detection | 28 |
higher prevalence | 28 |
gram staining | 28 |
may indicate | 28 |
clinical aspects | 28 |
filtration efficiency | 28 |
rsv positive | 28 |
hematological malignancies | 28 |
rapid molecular | 27 |
significant reduction | 27 |
binding sites | 27 |
must also | 27 |
driving pressure | 27 |
drug resistance | 27 |
less well | 27 |
large amounts | 27 |
standard treatment | 27 |
second week | 27 |
surveillance systems | 27 |
new cases | 27 |
virus identification | 27 |
clinical implications | 27 |
readily available | 27 |
innate antiviral | 27 |
asymptomatic individuals | 27 |
take place | 27 |
hantavirus pulmonary | 27 |
seeplex rv | 27 |
acid detection | 27 |
considered significant | 27 |
newborn infants | 27 |
therapeutic intervention | 27 |
respiratory insufficiency | 27 |
febrile seizures | 27 |
pneumococcal conjugate | 27 |
primary cause | 27 |
fully understood | 27 |
effective treatment | 27 |
also used | 27 |
specific ige | 27 |
inclusion bodies | 27 |
pcr detection | 27 |
hbov strains | 27 |
large proportion | 27 |
chest physiotherapy | 27 |
clinical information | 27 |
viral protein | 27 |
illness onset | 27 |
child health | 27 |
systematic reviews | 27 |
viral upper | 27 |
infected infants | 27 |
pediatric ards | 27 |
cardiopulmonary disease | 27 |
respiratory mucosa | 27 |
macrolide antibiotics | 27 |
new coronavirus | 27 |
one hundred | 27 |
basement membrane | 27 |
animal species | 27 |
matrix metalloproteinase | 27 |
nonhuman primates | 27 |
comparative study | 27 |
community outbreak | 27 |
free water | 27 |
care center | 27 |
years later | 27 |
samples positive | 27 |
children viral | 27 |
del virus | 27 |
lower tract | 27 |
clinical study | 27 |
meteorological factors | 27 |
multinucleated giant | 27 |
decision making | 27 |
alveolar spaces | 27 |
enteral feeding | 27 |
antibody production | 27 |
poor outcome | 27 |
patients presented | 27 |
primary outcome | 27 |
tract pathogens | 27 |
acute myocardial | 27 |
may progress | 27 |
recombinant human | 27 |
studied patients | 27 |
newly recognized | 27 |
transcriptase pcr | 27 |
still unclear | 27 |
antigenic drift | 27 |
transcription factors | 27 |
one week | 27 |
novel virus | 27 |
puede ser | 27 |
direct fluorescent | 27 |
every hours | 27 |
free radicals | 27 |
neutrophil recruitment | 27 |
cardiopulmonary bypass | 27 |
children worldwide | 27 |
human polyomaviruses | 27 |
disease course | 27 |
risk adults | 27 |
may show | 27 |
infections associated | 27 |
human metapneumoviruses | 27 |
nutritional support | 27 |
two types | 27 |
immunodefi ciency | 26 |
human studies | 26 |
essential oil | 26 |
winter seasons | 26 |
long periods | 26 |
cord injury | 26 |
organizing pneumonia | 26 |
two studies | 26 |
negative samples | 26 |
specific virus | 26 |
wu polyomavirus | 26 |
within weeks | 26 |
test result | 26 |
virus entry | 26 |
cotton rat | 26 |
foster city | 26 |
associated infection | 26 |
likely due | 26 |
allergic disease | 26 |
extracellular traps | 26 |
serologic testing | 26 |
goblet cells | 26 |
muscular dystrophy | 26 |
strand rna | 26 |
ari cases | 26 |
detected among | 26 |
genome sequencing | 26 |
first case | 26 |
sari case | 26 |
pulmonary pathology | 26 |
virus titers | 26 |
fungal infections | 26 |
i interferons | 26 |
northern hemisphere | 26 |
clinical setting | 26 |
vaccinia virus | 26 |
significant role | 26 |
higher frequency | 26 |
gram stain | 26 |
also present | 26 |
epidemiological profile | 26 |
may benefit | 26 |
person transmission | 26 |
common pathogen | 26 |
life cycle | 26 |
clinical syndrome | 26 |
pulmonary complications | 26 |
zoster virus | 26 |
younger age | 26 |
reading frame | 26 |
intubated patients | 26 |
suppurative bronchopneumonia | 26 |
mean airway | 26 |
eight patients | 26 |
administration period | 26 |
low mortality | 26 |
gross lesions | 26 |
ventilator settings | 26 |
mean difference | 26 |
military trainees | 26 |
sentinel surveillance | 26 |
attenuated vaccines | 26 |
type infection | 26 |
humanized monoclonal | 26 |
age children | 26 |
recently described | 26 |
without fever | 26 |
among humans | 26 |
may take | 26 |
liver transplantation | 26 |
virus surveillance | 26 |
pathogen detected | 26 |
first day | 26 |
genbank database | 26 |
thoracic cavity | 26 |
cigarette smoking | 26 |
potential therapeutic | 26 |
el cual | 26 |
lymphoid cells | 26 |
epidemiological features | 26 |
immune status | 26 |
newly emerging | 26 |
hospital outbreak | 26 |
beneficial effect | 26 |
mixed infection | 26 |
microbial communities | 26 |
cd cd | 26 |
prognostic factors | 26 |
scoring system | 26 |
neonatal foals | 26 |
protein kinase | 26 |
antigenic shift | 26 |
pediatric infectious | 26 |
smoke exposure | 26 |
signaling pathway | 26 |
antiviral drug | 26 |
mediated immune | 26 |
center experience | 26 |
analysis revealed | 26 |
artery catheter | 26 |
pcr results | 26 |
mers patients | 26 |
respiratory bacterial | 26 |
longitudinal studies | 26 |
responses may | 26 |
recently identified | 26 |
may influence | 26 |
immune dysregulation | 26 |
respiratory picornaviruses | 26 |
human bronchial | 26 |
fibrinous bronchopneumonia | 26 |
septic patients | 26 |
femoral head | 26 |
human infections | 26 |
antimicrobial resistance | 26 |
disease complex | 26 |
major outbreak | 26 |
inflammatory cell | 26 |
en este | 26 |
diffuse interstitial | 26 |
frequently identified | 26 |
pneumonia patients | 26 |
index case | 26 |
time series | 26 |
health status | 25 |
artery pressure | 25 |
microscopic examination | 25 |
el momento | 25 |
first choice | 25 |
influenza epidemics | 25 |
viral isolation | 25 |
diagnostic criteria | 25 |
clinical progression | 25 |
hcov nl | 25 |
tract diseases | 25 |
indoor air | 25 |
cell subsets | 25 |
infected persons | 25 |
infants aged | 25 |
information regarding | 25 |
calculated using | 25 |
low sensitivity | 25 |
bronchial epithelium | 25 |
human population | 25 |
approximately one | 25 |
using spss | 25 |
ciliated epithelial | 25 |
therapeutic options | 25 |
haematopoietic stem | 25 |
guinea pig | 25 |
vaccine strain | 25 |
secondary cases | 25 |
immune deficiency | 25 |
aged younger | 25 |
adenovirus pneumonia | 25 |
frequently used | 25 |
final manuscript | 25 |
low birth | 25 |
myasthenia gravis | 25 |
nine patients | 25 |
associated acute | 25 |
current evidence | 25 |
cardiac failure | 25 |
aged months | 25 |
mrna expression | 25 |
several years | 25 |
conjugate vaccine | 25 |
picornavirus infections | 25 |
respiratory swabs | 25 |
protective immune | 25 |
cdna synthesis | 25 |
pulmonary mechanics | 25 |
data regarding | 25 |
pathogens causing | 25 |
lung tissues | 25 |
described elsewhere | 25 |
reactive airway | 25 |
airways disease | 25 |
peak expiratory | 25 |
rsv pneumonia | 25 |
i pneumonocytes | 25 |
hospital treatment | 25 |
broadly neutralizing | 25 |
prevention strategies | 25 |